The circulating cell-free tumor DNA market involves products and tools utilized for isolating and analyzing circulating tumor DNA fragments present in blood or other body fluids. Circulating cell-free tumor DNA serves as a non-invasive alternative to tissue biopsies and provides important insights into somatic mutations present in tumors. They aid doctors in monitoring treatment response, detecting recurrence, and better understanding the genetic underpinnings of disease. The demand for circulating cell-free tumor DNA-based liquid biopsy solutions is rising given their advantages over traditional tissue biopsies like being minimally invasive, cost-effective and allowing multiple samples to be collected over time. The Global circulating cell-free tumor DNA Market is estimated to be valued at US$ 7.03 Mn in 2024 and is expected to exhibit a CAGR of 6.4% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the circulating cell-free tumor DNA are BASF SE, Perstorp Holding AB, Chemoxy International Ltd., and Merck Group. BASF SE is one of the leading players offering a wide range of technologies and kits for ctDNA isolation and analysis. Perstorp Holding AB is a prominent manufacturer of specialized chemical precursors used in major circulating cell-free tumor DNA testing product lines.
The demand for circulating cell-free tumor DNA-based diagnostics and monitoring solutions is anticipated to grow significantly over the forecast period. The advantages of liquid biopsies over traditional tissue biopsies and the growing scope of applications in cancer care are fueling adoption. Furthermore, the development of sensitive technologies allowing detection of even low circulating tumor DNA levels is also propelling the market growth.
Advances in next-generation sequencing and digital PCR technologies have enabled highly accurate and inexpensive profiling of ctDNA. Companies are developing specialized panels and kits for ctDNA analysis in various cancer types which is helping maximize clinical utility. Point-of-care devices and tests allowing ctDNA analysis in decentralized settings are also gaining traction.
Market Trends
The two key trends in the circulating cell-free tumor DNA market include-
1) Growing preference for multi-cancer early detection tests: Vendors are developing blood tests that can simultaneously detect multiple cancer types from a single sample of blood. Such comprehensive liquid biopsy solutions are witnessing higher demand.
2) Integration with artificial intelligence and machine learning: AI and ML approaches are being integrated with ctDNA analysis platforms to improve detection capabilities. This helps derive more accurate insights from complex genomic data.
Market Opportunities
The major opportunities in the circulating cell-free tumor DNA market are:
1) Emerging economies in Asia Pacific and Latin America: With improving healthcare infrastructures and rising healthcare spending, these regions provide lucrative growth opportunities.
2) Integration with cancer management workflows: Further development of clinical trials and clinical decision support tools integrating ctDNA data can help cement its role in routine cancer management. This ensures continued uptake.
Impact of COVID-19 on Circulating Cell-Free Tumor DNA Market Growth
The COVID-19 pandemic significantly impacted the Circulating Cell-Free Tumor Dna Market Size in 2020 and 2021. During the peak of the pandemic in 2020, most hospitals and diagnostic centers shifted their focus and resources towards COVID-19 patients. As a result, non-emergency procedures including cancer screening and tumor DNA testing saw a significant decline. This negatively impacted the demand for circulating cell-free tumor DNA tests in 2020.
However, as medical facilities adapted to the new normal with strict safety protocols, cancer screening and diagnosis slowly resumed in 2021. While demand was recovering, supply chain disruptions and lockdowns in various parts of the world led to shortages of crucial reagents and kits required for circulating cell-free tumor DNA tests. This delayed market growth recovery during the early stages of 2021.
Going forward, post COVID, the market is anticipated to grow at a fast pace. The pandemic emphasized the need for non-invasive liquid biopsy tests for cancer screening and management. As a result, investment and focus on research and development of advanced circulating cell-free tumor DNA tests are expected to increase significantly. Adoption of tumor DNA tests is also expected to rise globally as countries address the backlog in cancer cases created during the peak pandemic period. However, companies will need to diversify supplier bases and build flexibility in supply chains to address future disruptions.
North America has been the largest regional market for circulating cell-free tumor DNA globally in terms of value. This is attributed to the well-developed healthcare infrastructure and higher adoption of advanced diagnostic tests for cancer in countries like the US. Further, presence of leading market players has ensured wide availability of different tumor DNA tests. However, the Asia Pacific region is expected to be the fastest growing market during the forecast period. This rapid growth will be driven by rising healthcare expenditure, growing cancer burden, and increasing focus on early cancer detection in emerging countries like China and India.
Get more insights on Circulating Cell-Free Tumor Dna Market
Also read related article on Cell Cryopreservation Market
Circulating Tumor Cell Diagnostics are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication.
Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients.
It includes enrichment, detection and analysis of the detected circulating tumor cells.
Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis.
CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancerKey questions addressed by the reportWhere will all these developments take Circulating Tumor Cell Diagnosticsin the mid- to long-term?What are the upcoming technological trends in the Circulating Tumor Cell Diagnosticsmarket?What are the opportunities for various players that exist at present and those that are planning to enter at different stages of the value chain?How growth strategies implemented by key players will impact the growth rate of the Circulating Tumor Cell Diagnosticsmarket, and who will have the undue advantage?What are the current adoption trends of the Circulating Tumor Cell Diagnosticsmarket?Report Sample includes:- Table of Contents- List of Tables & Figures- Charts- Research MethodologyGet FREE Sample of this Report at https://www.24marketreports.com/report-sample/global-circulating-tumor-cell-diagnostics-2019-624Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells.
Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics.
Circulating Tumor Cell Market OverviewIn 2017, the global market size of circulating tumor cell (CTC) reached a valuation of USD 9,393.1 Mn.
The market is projected to surpass a valuation of USD 28,300 Mn by the end of 2023, reflecting a healthy growth rate.The prevalence rate of CTC has gone up in recent years.
The mechanism of CTC is responsible for a vast majority of deaths caused by cancer.
Circulating tumor cells can be associated with different types of cancer prognosis including breast cancer, prostate cancer, and gastric cancer among others.
Healthcare companies continue to focus on developing solutions that enable accurate and quick detection of CTC.
The diagnosis and analysis of CTCs can help in early cancer detection and determine appropriate treatments tailored for specific cancer types.The “Circulating Tumor Cell Market” In-Depth competition analysis of the major companies in the report, sector of the report includes the market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue.The Circulating Tumor Cell Market provide valuable insight with an emphasis on the global market including some of the major players such As, Ikonisys Inc., Greiner Bio-One International GmbH, Thermo Fisher Scientific, SRI International, STEMCELL Technologies, Miltenyi Biotec, Menarini Silicon Biosystems, QIAGEN Hannover (QIAGEN), F. Hoffmann-La Roche Ltd, NanoString Technologies, Inc, Fluxion Biosciences, Inc., GE Healthcare, ApoCell, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), Epic Lifesciences, Celltraffix Inc.Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region.
